Compare
Teva Pharmaceutical Industries Ltd vs Viatris Inc vs Vertex Pharmaceuticals Inc vs Zoetis Inc.
| Latest fiscal year | Teva Pharmaceutical Industries Ltd TEVA | Viatris Inc VTRS | Vertex Pharmaceuticals Inc VRTX | Zoetis Inc. ZTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $17.26B | $14.30B | $12.00B | $9.47B |
| Revenue growth (YoY) | +4.3% | -3.0% | +8.9% | +2.3% |
| Gross margin | 51.8% | 35.1% | 86.2% (computed) | 71.8% (computed) |
| Operating margin | 12.5% | -18.6% | 34.8% | n/a |
| Net margin | 8.2% | -24.6% | 32.9% | 28.2% |
| Net income | $1.41B | -$3.51B | $3.95B | $2.67B |
| EPS (Diluted) | $1.21 | -$3.00 | $15.32 | $6.02 |
| Operating cash flow | $1.65B | $2.32B | $3.63B | $2.90B |
| Free cash flow | $1.15B | $1.94B | $3.19B | $2.28B |
| Cash & equivalents | $3.56B | $1.32B | $5.08B | n/a |
| Total assets | $40.75B | $37.19B | $25.64B | $15.47B |
| Total liabilities | $32.83B | $22.48B | $6.98B | $12.14B |
| Shareholders' equity | $7.91B | $14.71B | $18.67B | $3.33B |
| Return on year-end equity | 17.8% | -23.9% | 21.2% | 80.2% |
| Shares outstanding | n/a | n/a | 253.99M | 424.93M |
Revenue, most recent five fiscal years
| Fiscal year | Teva Pharmaceutical Industries Ltd | Viatris Inc | Vertex Pharmaceuticals Inc | Zoetis Inc. |
|---|---|---|---|---|
| Latest | $17.26B Ended 2025-12-31 | $14.30B Ended 2025-12-31 | $12.00B Ended 2025-12-31 | $9.47B Ended 2025-12-31 |
| 1 year earlier | $16.54B Ended 2024-12-31 | $14.74B Ended 2024-12-31 | $11.02B Ended 2024-12-31 | $9.26B Ended 2024-12-31 |
| 2 years earlier | $15.85B Ended 2023-12-31 | $15.43B Ended 2023-12-31 | $9.87B Ended 2023-12-31 | $8.54B Ended 2023-12-31 |
| 3 years earlier | $14.93B Ended 2022-12-31 | $16.26B Ended 2022-12-31 | $8.93B Ended 2022-12-31 | $8.08B Ended 2022-12-31 |
| 4 years earlier | $15.88B Ended 2021-12-31 | $17.89B Ended 2021-12-31 | $7.57B Ended 2021-12-31 | $7.78B Ended 2021-12-31 |